文献速递遗传性与小管间质肾病慢性肾脏病水电解质与酸碱

先天性精氨酸加压素抵抗患者的表型与肾脏结局

Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

中位随访16.6年,26%进展至慢性肾脏病(CKD III-V期),其中3例依赖透析。起病年龄早、血渗透压高、日尿量大及首次就诊时肾积水是CKD进展的独立危险因素。

要点

  • 非梗阻性肾积水是先天性AVP-R常见并发症。
  • 表型严重的患者易进展至CKD,与AVPR2或AQP2突变类型无关。
  • 起病早、高血渗透压、大尿量及肾积水提示CKD进展风险高。

核心结论

  • 非梗阻性肾积水在先天性AVP-R中常见,表型严重者常进展至CKD,且不依赖AVPR2或AQP2突变。

主要发现

  • 17例来自12个X连锁隐性遗传家庭携带11种AVPR2突变,包括3种新发小缺失和2种大缺失。
  • 8例来自5个常染色体隐性遗传家庭携带3种AQP2突变(Q57P、G100V、V168Rfs*32),2例来自1个常染色体显性遗传家庭携带新发AQP2 R253Dfs*82突变。
  • 多尿、多饮起病中位年龄0.7岁(范围2个月-2.5年),临床诊断AVP-R中位年龄11.7岁(范围0.7-21.5年)。
  • 7例(26%)在中位随访16.6年(范围2.2-25.7年)时进展至CKD III-V期,其中3例依赖透析。
  • 起病年龄早、血渗透压高、日尿量大及首次就诊时肾积水是CKD进展的独立危险因素。

关键数值与推荐

  • 四分之三患者接受口服氢氯噻嗪单药或联合阿米洛利治疗,三分之一接受吲哚美辛。
  • 7例患者存在持续性非梗阻性肾输尿管积水。
  • 一个携带AVPR2 F178L突变的家庭内观察到表型异质性。

临床怎么用

  • 对先天性AVP-R患者应评估肾积水及CKD进展风险,起病早、高血渗透压、大尿量者需密切随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: The clinical phenotype and long-term outcomes of patients with congenital arginine vasopressin-resistance (AVP-R) have not been well evaluated. This study investigated the clinical features, treatment modalities and renal outcomes of patients with AVP-R. METHODS: Twenty-seven patients (male:female = 21:6, mean age = 22 ± 17 years) with genetically confirmed AVP-R from 18 unrelated Taiwanese families were included. Genomic DNA extracted from blood leukocytes was analyzed for AVPR2 and AQP2 mutations. Clinical presentations, laboratory findings, management and follow-up data, including analyses of renal function changes, were evaluated. RESULTS: Seventeen patients from 12 X-linked recessive families harbored 11 different AVPR2 mutations, including three novel small deletions and two large deletion mutations. Eight patients from five autosomal recessive (AR) families harbored three different AQP2 mutations (Q57P, G100V, V168Rfs*32) and two patients from one autosomal dominant (AD) family harbored a novel AQP2 R253Dfs*82 mutation. The median ages at onset of polyuria and polydipsia and at clinical diagnosis of AVP-R were 0.7 (range 2 months-2.5 years) and 11.7 (range 0.7-21.5) years, respectively. Three-quarters of patients were treated with oral hydrochlorothiazide alone or combined with amiloride, and one-third received indomethacin. Intrafamilial phenotypic heterogeneity was observed in one family harboring the AVPR2 F178L mutation. Seven patients exhibited persistent non-obstructive hydroureteronephrosis. At a median follow-up of 16.6 (2.2-25.7) years, seven patients (26%) had progressed to chronic kidney disease (CKD, stage III-V), of whom three (AVPR2 mutation = 2, AD AQP2 R253Dfs*82 = 1) were dependent on dialysis. An earlier age of onset, higher serum osmolality, larger daily urine volume and hydroureteronephrosis at first presentation were independent risk factors for CKD progression. CONCLUSIONS: Non-obstructive hydroureteronephrosis is a common complication of congenital AVP-R. CKD frequently develops in patients with phenotypically severe congenital AVP-R, independent of AVPR2 or AQP2 mutation.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Tseng MH, Sung CC, Cheng CJ, et al. Phenotype and renal outcomes of patients with congenital arginine vasopressin resistance. Nephrol Dial Transplant. 2026. PMID: 41129383. doi:10.1093/ndt/gfaf218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。